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Abstract: Today’s proteomic analyses are generating increasing numbers of biomarkers, 
making it essential to possess highly specific probes able to recognize those targets. 
Antibodies are considered to be the first choice as molecular recognition units due to their 
target specificity and affinity, which make them excellent probes in biosensor development. 
However several problems such as difficult directional immobilization, unstable behavior, 
loss of specificity and steric hindrance, may arise from using these large molecules. 
Luckily, protein engineering techniques offer designed antibody formats suitable for 
biomarker analysis. Minimization strategies of antibodies into Fab fragments, scFv or even 
single-domain antibody fragments like VH, VL or VHHs are reviewed. Not only the size of 
the probe but also other issues like choice of immobilization tag, type of solid support and 
probe stability are of critical importance in assay development for biosensing. In this 
respect, multiple approaches to specifically orient and couple antibody fragments in a 
generic one-step procedure directly on a biosensor substrate are discussed. 
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1. Antibodies in sensor applications 
Over the past few years, multiple protein biomarkers have been suggested as a diagnostic target 
based on genomic or proteomic studies. Devices such as biosensors that could measure those 
biomarkers rapidly (e.g. within 10 minutes) and at very low concentrations (e.g. at fg/ml) would be 
advantageous in diagnostic development. In particular, the capacity of the biosensor to meet challenges 
such as sensitive detection and low-level quantification of analytes, will undoubtedly put them more in 
the spotlight1. Biosensors are built up of a biological target-recognition element that is connected to a 
transduction element using a suitable interface layer. Binding events occurring at this functionalized 
interface layer are translated by the transducer into a comprehensive read-out2. These biosensors 
provide a rapid, convenient, low cost alternative to conventional analytical methods such as HPLC, 
ELISA, 2-D gel electrophoresis or mass-spectrometry, for detecting or assaying a biomarker. 
One particular category of biosensors is the antibody-based biosensor or immunosensor. This type 
of biosensor relies on the ability of an immobilized antibody (Ab) to recognize its associated target, 
known as antigen (Ag). For biosensor development these Ab-based probes should meet very high 
standards such as high specificity in a very complex medium, well-characterized binding properties, 
high stability and the possibility of large-scale production preferably at low cost3. Another important 
aspect in biosensor design is the quality of the interface layer between probe and transduction element 
since it will also determine both the sensitivity and the specificity of the biosensor. Here several 
problems may arise, as proteins and Abs in general are chemically and structurally complex and 
heterogeneous. This makes them often unpredictable regarding their interactions with the biosensor 
substrate4. Therefore, it is difficult to define a general protein detection and immobilization strategy5.  
Immunoassays based on polyclonal (pAb) and monoclonal (mAb) antibodies have been around for 
more than 30 years and are still among the most important diagnostic tools widely used in clinical and 
research areas6. The pAbs can easily be generated, but batch-related differences, varying affinity and 
poly-specificity (i.e. reactivity with more than one target) can create serious problems, certainly when 
used as a probe in biosensors7. In contrast, a mAb can be selected to be more specific for a unique 
epitope present on the protein of interest and/or its variant(s). In addition, any particular mAb can - in 
principle - be obtained reproducibly in unlimited quantities and its target-affinity can at least be 
determined. Their identification is amenable to a high-throughput mode by immunizing animals with 
antigen mixtures followed by automated screening so that large numbers of additional binders per 
annum are within reach. Moreover, many mAbs are already used as affinity reagents for identification, 
validation, quantification, localization, functional analysis and ablation of proteins8.  
Nowadays, these Abs are proposed as prime candidates to be used as probes in biosensors. Despite 
some successes, a reasonable fraction of the mAbs selected for specific analyte recognition fails to 
function properly in the biosensor setup due to unpredictable conformation changes on surfaces, or 
unwanted reactivities mediated by their Fc part. Therefore Abs have previously been minimized into 
different Ab formats and optimized for affinity and/or stability to improve development of a robust Ab-
based probe for biosensor applications9. In addition, it has become obvious that immobilization 
engineering is a mandatory step in the development10. In many cases loss of biological activity upon 
immobilization of Abs is noticeable. One reason might be the random orientation of the Abs on sensor 
surfaces whereby optimal Ag binding is prohibited compared to soluble Abs11.  
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2. Available antibody fragment formats 
Since the introduction of recombinant Ab engineering, the size of mAbs has been minimized and 
adapted into different formats suitable for the envisaged application8. The well-established smaller 
engineered format of a mAb is the Fab fragment containing the complete Light-chain (VL and CL 
domain) and the first half of the Heavy-chain, the Fd (VH and CH1 domain) (Figure 1A). The Fab 
encompasses the Ag-binding domain without the effector function fragment, the Fc part. Even smaller 
fragments can be designed from the Fab fragment, e.g. an Fv and the single-chain Fv  
(scFv) fragment12.  
With a small flexible polypeptide linker between VH and VL domain, the scFv fragment is 
generally more stable than the Fv fragment, which leads to higher functionality13. Unfortunately, this 
synthetic linker causes dimerization and aggregation of the scFv, subsequently fuelling many 
investigations into more stable Ag-binding Ab fragments14, e.g. the scFab13. The smallest possible Ag-
binding Ab fragment from a mAb is made up of just one variable domain, e.g. the VH or VL14. 
Unfortunately these fragments have a pronounced tendency to form aggregates as these isolated single-
domains often expose large hydrophobic regions to the solvent. 
Figure 1. Ab fragments from conventional (A), Heavy-chain (B) and cartilaginous fish (C). 
 
Antibodies have dogmatically been described as being composed invariably of two identical Heavy-
chains and two identical Light-chains. The species of the Camelidae (i.e. Camelus dromedarius, C. 
bactrianus, Lama glama, L. guanoco, L. alpaca and L. vicugna) however produce a surprising 
exception to this paradigm. Their serum contains a considerable fraction of Heavy-chain Abs (HCAbs), 
that lack the Light-chain15 (Figure 1B). The Heavy-chain within the HCAbs is composed of three 
instead of four globular domains. The two constant domains are highly homologous to the CH2-CH3, 
Fc domains of classical Abs16. Remarkably, the domain corresponding to the CH1 domain of classical 
Abs is missing in HCAbs. Hence, the Ag-binding fragment of a classical Ab, the Fab, is reduced to a 
single variable domain in the HCAb. This variable domain referred to as VHH17 or Nanobody18 is 
adapted to become functional in Ag-binding in absence of a variable Light-chain domain (VL)19. It has 
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been repeatedly demonstrated that the VHH, cloned and expressed in bacteria, is a strictly monomeric, 
single-domain Ag-binding entity20. Even more recently, an alternative natural single domain antibody 
format was discovered in cartilaginous fish, e.g. sharks. A new and probably ancestral immunoglobulin 
isotype termed “novel antigen receptor” (Ig-NAR) was described21. Similar to HCAbs in camelids, this 
new isotype is a Heavy-chain homodimer. The Ig-NAR is a disulfide bonded homodimer of two 
identical H-chains that lacks light chains. Each H-chain contains one variable domain (V-NAR) and 
five constant domains (Figure 1C). 
The reduced size, improved solubility and higher stability of the camelid Heavy-chain and shark Ig-
NAR antibody fragments are of special interest for biotechnological and medical applications, 
including biosensors22. 
3. Generation of antibody fragments libraries 
Recombinant Ab technologies to engineer mAbs into smaller Ab fragments, although very 
promising, may cause loss of affinity, increased tendency to aggregate, increased temperature 
sensitivity, and low yield of protein functional in Ag recognition. Moreover the isolation and 
subsequent purification of mAbs is a very costly and time-consuming process. These issues can be 
circumvented by selecting Ag-binding Ab fragments from libraries using in vitro screening 
technologies and bacterial expression of the selected clone. This construction of highly diverse 
expression libraries of Ag-binding Ab fragments based on combinatorial principles is the first key 
technology en route to obtain optimal Ab-based probes. An Ab fragment library is usually derived from 
a single scaffold such as Fab, scFv or VH. Essentially, variability is generated at several regions of the 
Ag-binding moiety in many different ways; from the random combination of VH and VL domains, to 
the introduction of variability into the antibody scaffold using synthetic23; 24 or semisynthetic25; 26 
approaches. Several methods were already optimized and resulted in the construction of large scFv 
libraries27; 28; 29. Such hyperdiversified Ab fragment libraries enabled the selection of Ab fragments 
specific to virtually any target. Besides these synthetic libraries, Ab fragments can be selected from a 
camelid non-immune library30 or immune libraries against a wide variety of antigens18; 31; 32; 33. 
Subsequent isolation of Ag-specific Ab fragments from these libraries can be performed via different 
screening techniques. 
4. Selection of antigen-specific antibody fragments 
In order to isolate highly potent Ab-based probes from these large libraries, so-called display 
technologies are the second key technology to identify probes.  Display technologies physically link the 
probes’ genotype with its phenotype, and allow very efficient handling of large expression libraries 
(sometimes encompassing > 1010 individual clones). Various forms of display technologies such as 
phage display34; 35; 36, ribosome display37; 38; 39; 40 or mRNA display41 libraries have been reported. 
Ribosomal display has the advantage that it does not require bacterial host cells, and thus there is 
nearly no limit in extension of library complexity. Here genotype and phenotype are linked through 
ribosomal complexes, consisting of mRNA lacking a stopcodon, ribosome and encoded protein that are 
used for selection. However due to the high technological demands of ribosome display, widespread 
application of this technology has been hampered.  
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The most robust of these in vitro selection procedures - and by far the most widely used - is phage 
display. Phage display has been utilized for isolating recombinant Ab fragments. After construction of 
an Ab combinatorial library, Ag-specific recombinant Ab fragments can be easily isolated by bio-
panning of the phage library displaying Ab fragments fused with viral coat protein III against antigen 
proteins, antigen-expressing live cells, or fixed cells36. Several steps in Ab phage display may be 
improved by: (i) increasing the size of the library to enlarge the chances to select for high affinity 
binders within the repertoire, (ii) adapting the bio-panning procedure for isolation of Ab fragments 
reactive with immunological minor epitopes42, (iii) enhancing the expression level and stability of the 
selected Ab fragments and (iv) engineering of the expression phagemid cloning vector43.  
Combining the Ab fragment libraries with powerful phage display has led to a multitude of 
generated Ab fragments. Although these various technologies allow the isolation of highly specific 
antibody fragments, these fragments do not necessarily meet the functional standards required for 
successful employment in a biosensor format. These problems can be overcome by use of optimized 
scaffolds44 or stress driven selections (e.g. temperature45 or chemical denaturing32). Once a suitable Ab 
fragment has been selected to bind a diagnostically relevant epitope, further engineering can be 
performed to increase antigen affinity, probe stability or immobilization potential. Different approaches 
to further improve the Ab properties towards ideal biosensor probes are described below. 
5. Affinity engineering 
High-affinity is a prerequisite for the development of simple and highly sensitive biosensors. 
Sometimes the Ab fragments selected via display technologies fail to meet the required kinetic-affinity 
parameters of target association/dissociation to develop an optimal sensor assay. Ideally, the kon value 
(i.e. the kinetic association rate) needs to be above 105 M-1 s-1 for rapid assay results (less than 15 
minutes). The koff value (i.e. kinetic dissociation rate) seems to be less critical, and values from 10-3 s-1 
are appropriate for acceptable target release. Panning of immune libraries usually yields Ab fragments 
that bind with nanomolar affinity (KD=koff/kon) to their cognate target. However, binders retrieved after 
panning of (semi-) synthetic libraries do not routinely reach such low KD values. The improvement of 
affinity of an Ag-Ab interaction, although challenging, can be tremendous beneficial to develop a 
sensitive biosensor. Several techniques such as random mutagenesis, direct evolution, ribosome 
display, etc. can be included to optimize the Ab fragments towards a more suitable kon or koff value. 
Affinity maturation via a combination of molecular evolution and high-throughput methods (e.g. via 
ribosome display) is preferred. This combination has resulted in the isolation of specific antibody 
fragments from naïve libraries, with sufficient affinity for analyte biosensing applications46. 
6. Stability engineering 
An overlooked parameter of Ab fragments for immunosensor development is the intrinsic stability. 
Not only is long-term storage and re-usability of Ab chips important from a practical point of view, but 
also stability during manufacturing it is a critical factor. Therefore high demands are placed on the 
functional stability of the probes for biosensors.  
The Fv and scFv fragments engineered from mAbs or selected from combinatorial libraries do not 
always reach the required stability treshold47; 48.  Upon construction of Fv and scFv fragments, the 
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variable domains are removed from their natural Fab context, where they are associated with the 
constant domains of the Light-chain (CL) and Heavy-chain (CH1). Despite mutual stabilization of the 
domains in a scFv, most scFv derived from mAbs show poor to moderate stability without additional 
engineering12. Many research groups have solved the problem of the limited stability of the Fv Ab 
fragment via different routes. Both VL and VH domains can be fused into many alternative formats, 
besides the conventional scFv format. In a first format the CH1 and CL domain of the Fab fragment are 
replaced with a heterodimeric coiled coil, resulting in a helix-stabilized Fv fragment (hsFv)49. In a 
second format, the disulfide-stabilized Fv fragment (dsFv), a cysteine residue is introduced into the 
conserved framework regions of both the VH and VL at positions compatible with the formation of an 
interdomain disulfide linkage. This dsFv can bind antigen with identical affinity, and proved to be 
substantially more resistant to heat or urea treatment than the scFv50. Another format to stabilize the 
scFv is obtained by introducing a disulfide bond into the scFv which results in a ds-scFv, combining 
the stability of the disulfide form with the expression advantages of the scFv51. The reformatting of the 
scFv into a Fab fragment is an alternative strategy that leads towards an improved functional stability 
of the Ab fragment. Such approach might - in some cases - replace the additional maturation steps, 
when the affinity and stability are close to the limit of tolerance for a successful biosensor assay52. 
However, it is rather preferred to minimize the dimensions of the antibody-based probes to get a 
maximal amount of probe onto the sensor surface, than enlarging the probe into a Fab.  
Besides applying optimized formats, the variable domains of suboptimal stability can be engineered 
for improved robustness and folding efficiency while preserving their Ag-binding specificity and 
affinity. This can be performed either by introducing a limited number of point mutations53 or by 
grafting their Ag-specificity onto variable domains with frameworks of superior stability. The grafting 
technique, originally utilized to humanize Abs, involves loop grafting of the CDR-loops of less-stable 
Ab fragments onto a highly stable framework, resulting in a reshaped Ab fragment with the Ag 
specificity of the donor Ab and the stability of the acceptor framework25. Grafting onto scFv was 
shown on multiple occasions54; 55. In case of camelid Heavy-chain Ab fragments similar results were 
obtained, i.e. a universal loop acceptor VHH-scaffold was identified and revealed to be able to harbor 
loops from different VHHs. This allows stabilization of Nanobodies for employment as probes in 
biosensors or microarrays56. Recently, a novel method for increasing the intrinsic stability of Ab 
fragments was proposed. By inserting a disulfide bond in the hydrophobic core of any variable Ab 
domain, the chemical and thermal stability could be increased57; 58. 
The above mentioned techniques are used when the Ab-based probe is already available and 
stability improvement is required. To increase the level of throughput in Ab-based probe generation, 
combinatorial libraries can be used in conjunction with stress-guided selection techniques. This 
resulted already in several general strategies for probe generation59; 60; 61.  
The Ab intrinsic stability is important during probe regeneration. Biosensor applications involving 
multiple detection cycles are critically dependent on the feasibility to fully regenerate the probe, i.e. the 
complete removal of captured analyte from the probe in between two detection cycles. Such 
regenerations might create an additional difficulty when the cleaning conditions destroy the activity of 
the probe. It becomes even more difficult for probe-analyte complexes with high affinity constants. 
These will require extreme conditions to disrupt their interaction. Backmann et al. 47 reported on a 
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label free immunosensor using single-chain antibody fragments where repeated regeneration with low-
pH buffer resulted in loss of binding activity. This indicated that the covalent immobilized scFv 
fragments might undergo unfolding and denaturation upon harsh regeneration. Since intrinsic stability 
of the probe has been shown to be an important parameter for optimal biosensor design62, problems 
with regeneration can be circumvented by selecting Ab-based probes with high intrinsic stability. 
7. Immobilization of antibody fragments 
The attachment of active recognition molecules at high-density to the transducer surface is one of 
the most critical steps in biosensor development. Proper strategies for Ab immobilization will mainly 
be determined by the solid sensing substrate and the properties of the interface layer. The most suitable 
method of Ab immobilization therefore varies with the type of biosensor that needs to be coated with 
the desired probe. The full-sized Ab has estimated molecular dimensions of 15 x 7 x 3.5 nm10, whereas 
the smallest Ab fragments, i.e. single-domain Ab fragments, are only 4 x 2.5 x 3.5 nm. Moreover, the 
Ab-Ag interaction is also affected by the nature of the interface layer between the immobilized Ab and 
the sensor surface63. Ideally, the probe should specifically recognize and bind its antigen at the lowest 
possible concentration. Since the biosensor surfaces are in the µm scale, the smaller the Ab fragment, 
the more probes can be immobilized onto the surface, resulting in an enhanced detection sensitivity64. 
Unfortunately it has been observed regularly that proteins, and Abs in particular, may lose (part of) 
their biological activity when immobilized on a surface. This can be attributed to a combination of two 
factors: change in conformation upon cross-linking and/or unfavorable orientation of the  
probes65 (Figure 2A). 
Physical adsorption is the simplest process of protein binding, although rather uncontrollable. It 
occurs through hydrophilic, hydrophobic or both types of interactions between Abs and the sensor 
surface. Random orientation of the absorbed Abs and close proximity between adsorptive surface and 
the Ag-binding site could impede the detection (Table 1).  
Covalent attachment of Abs on chemically-activated sensor surfaces is the most common method 
for Ab immobilization. Numerous chemical coupling reagents (e.g. glutaraldehyde, carbodiimide or 
succinimide ester) to cross-link mainly carboxylated functional groups have been tested to immobilize 
Abs onto various solid surfaces. Most commonly used covalent immobilization approaches couple the 
Abs randomly via their free amino-groups to the chemically-activated sensor surface. Such covalent 
binding of proteins to a biosensor surface represents a rational and robust approach (Table 1).  
However, numerous studies over the past 40 years have shown that the physical adsorption or the 
covalent attachment procedures of antibodies onto solid supports increase the probability of 
denaturation or conformational change (Table 1). After surface immobilization, mAbs and recombinant 
Ab fragments exhibit non-uniform kinetic and thermodynamic properties with the respective Ag. A 
general solution is to uniformly orient the probes and increase the accessibility of their Ag-binding 
domains66 (Figure 2B). 
Overall, the directional immobilization processes share several advantages. Usually, the Ag-binding 
domains of the probe are better accessible to the analyte when the surface-coupling site within the 
probe is at a distant position from the Ag-capturing site. Within the Ab population, the Ag-binding 
kinetics upon covalent immobilization remains more uniform and this can affect the biosensor 
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sensitivity positively67. This was emphasized by Bonroy et al. 68 when they showed for a particular Ab-
Ag pair that the optimized fragmentation protocol in combination with an oriented immobilization of 
Fab fragments on mixed self-assembled monolayers (SAMs) led to a more than two-fold increase of 
the Ag binding signals compared to randomly covalent immobilized full-length Abs.  
Table 1. Advantages and disadvantages of different Ab fragment immobilization methods. 
Immobilization method Advantages Disadvantages 
Adsorption Minimal manipulation 
No Ab modification 
Mostly high immobilization level 
Random orientation 
Ab denaturation 
Non-specific protein binding 
Leakage of Ab from surface 
Covalent coupling Stable immobilization 
Commercially available surfaces 
Random orientation 
Ab modification, possible denaturation 
Ab fragment tag  Oriented immobilization 
Mild incubation 
Surface stability 
Ab-binding proteins Oriented immobilization 
No Ab modification 
Mild incubation 
Surface stability 
Ab fragment fusions Oriented immobilization 
Surface stability 
Compatibility between Ab fragment and 
fusion partner 
 
Figure 2. Ab fragment immobilization via random (A) or oriented (B) covalent coupling. 
 
There are different approaches to obtain oriented immobilization of the probes. A first simple 
immobilization strategy involves the direct chemical coupling of the probe onto the transducer, e.g. a 
non-coated gold surface and available –SH groups on the probe69. Another methods uses a variety of 
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chemical reactions to attach the probe via the –SH group to the gold substrate that is coated with a 
dextran layer70 or sensor or with self-assembled monolayers (SAMs) of thiols2 (Figure 2B). Ab 
fragments such as a Fab fragment, could be immobilized via the native thiol group more easily after 
reduction of the Fab2 fragment71. Even an engineered C-terminal cysteine residue at the light chain 
constant domain of a scFv fragment could be successfully applied to attach the probe via a 
heterobifunctional linker onto a gold surface72.  
As an alternative to direct chemical coupling, oriented immobilization can also be achieved 
indirectly, via an intermediate layer (the so-called ‘immobilization layer’), which is added between the 
gold thin-film and the immobilized Ab. An elegant example is by utilizing natural Ab binding proteins 
such as protein A or G for increasing biosensor sensitivity and specificity73. Ab-binding proteins such 
as protein A and G have been extensively employed to capture Abs on biosensor surfaces with their 
Ag-binding site maximally exposed to the solution and thus remaining fully functional4 (Figure 3).  
Figure 3. Ab fragment immobilization via intermediate layer. 
 
Another method for orienting Abs specifically onto surfaces consists of attachment of biotinylated 
Abs onto a (strept)avidin-modified surface (Figure 4). Ab fragments can be biotinylated by random or 
oriented labeling procedures. Random biotinylated scFvs can be coated onto surfaces at much higher 
densities than most commonly used Abs, improving the biosensor sensitivity and specificity74. Site-
directed biotinylation of Abs at their hinge region preferentially at the sulfhydryl groups between CH1 
and CL domains was developed to immobilize Abs in an oriented manner via biotin-streptavidin 
linkage. These site-directed biotinylated Abs showed consistently enhanced detection capabilities 
compared to random biotinylated Ab preparations75. Site-specific biotinylation can also be obtained via 
a novel method for generation of yeast-secreted, in vivo biotinylated recombinant antibodies, or 
biobodies76. The camelid single-domain antibody fragments can also be biotinylated in vivo at a site-
specific lysine residue within a designed tag and can thereafter be captured at high density in a directed 
orientation on a (strept)avidin coated biosensor substrate62.  
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Figure 4. Ab fragment immobilization via biotin-(strept)avidin interaction. 
 
Recently Ab fragments were genetically fused to a range of proteins and subsequently immobilized 
onto the sensor surface. Fusion of the Ab fragments to a universal immobilization domain will provide 
identical orientation of all molecules (Figure 5). Pleschberger et al.77 succeeded in fusing a bacterial S-
layer protein to a Nanobody. This fusion protein retained the ability to self-assemble onto solid surface 
into a square lattice structures with the Nanobody pointing outwards from the protein lattice surface 
into the solution. The monomolecular protein lattice could be exploited as a sensing layer in a 
biosensor setup. A similar approach was used for scFvs, whereby the fusion scFv with pIII surface 
protein allowed a more sensitive detection in their biosensor set-up78. Other chimeric proteins can be 
made via fusion of an Ab fragment with proteins such as beta-galactosidase, maltose-binding protein, 
calmodulin-binding protein, chitin-binding domain, cellulose-binding domain79 or glutathione-S-
transferase.  
Figure 5. Ab fragment immobilization via fusion partner. 
 
Since most recombinant Ab fragments are expressed with an affinity tag in order to facilitate 
purification, this tag is also proposed for immobilization onto a sensor surface (Figure 6). His-tag fused 
Ab fragments could be non-covalently immobilized onto Ni2+ or gold surfaces. Several scFv fragments 
were engineered to contain two histidines within the linker peptide used to join the scFv heavy and 
light chains80. These scFvs bound to the surface in a proper orientation, retained antigen-binding 
affinity, and could be coupled at high surface concentrations. By replacing the standard single His6-tag 
with a double-His6-tag on human recombinant scFvs, the binding onto Ni2+-nitrilotriacetic acid-coated 
substrates was significantly enhanced81. These improved binding characteristics enabled non-purified 
probes as present in crude expression supernatants to be directly applied thereby eliminating the need 
for any time-consuming pre-purification step(s) prior to the probe immobilization. 
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Figure 6. Ab fragment immobilization via affinity tag. 
 
Moreover Abs with a high affinity for certain types of materials could be advantageous in 
biomaterial science and be used in an approach to immobilize probes on a biosensor device. Special 
selected or constructed Ab fragments with high affinity for certain materials can be used, e.g. an Ab 
fragment that binds to polyhydroxybutyrate, a biodegradable polymer that is often used as biomaterial, 
was generated by a phage display system. This Ab fragment could be used in bispecific constructs for 
site-directed oriented immobilization of Ab fragments on this biomaterial82 (Figure 7). In addition Ab 
fragments with binding affinity and specificity for non-biological inorganic material surfaces (e.g. 
gold) were generated by grafting material-binding peptides into loops of the complementarity 
determining regions of Abs83.  
Figure 7. Ab fragment immobilization via bispecific construct containing a Ab 
fragment specific for the surface. 
 
8. Examples of antibody fragments in biosensor development 
Various studies on the use of antibody fragments as probes for biosensors were reported. For 
example Mechaly et al. 84 developed a scFv fragment for the efficient and specific detection of B. 
anthracis spores, and demonstrated its successful application in detection platforms like ELISA, IFA 
and FCM. Hu et al. 85 optimized a domoic acid-binding scFv antibody fragment and functionally 
immobilized it on a mesoporous silicate support for biosensor application development. Deng et al. 86 
isolated scFv fragments against Clostridium difficile toxin B. This scFv could detect toxin B to a 
minimum of 10 ng per well. These examples reveal how the recombinant antibody technology might 
assist in the rapid and effective development of next generation immunodiagnostic reagents. Huang et 
al. 64 developed a human prostate-specific antigen (PSA) biosensor based on a camelid single-domain 
antibody fragments. Via covalent immobilization of the VHH onto mixed SAMs and an optimized 
sandwich assay, clinically relevant concentration of PSA could be measured. In related research, 
different VHH constructs were immobilized onto commercial and custom-built sensor surfaces by 
metal chelation, biotin-streptavidin interactions or covalent coupling62. For the first time, the intrinsic 
stability was presented as an important probe design factor, as higher intrinsic stability offers higher 
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resistance to harsh environments. Finally, Carlsson et al. 87 used large-scale recombinant scFv antibody 
microarrays for the first time to classify metastatic breast cancer versus healthy controls, based on 
differential protein expression profiling of whole serum samples. The miniature assay set-up provided 
pM range sensitivities and > 95% specificity.  
9. Concluding remarks 
A biosensor is envisaged as a compact, portable device which is (i) very useful in remote or 
developing regions without easy access to sophisticated laboratory facilities, (ii) amenable to mass 
production and (iii) minimized for development into a handheld, point-of-care-device88. Many 
biomarkers have been originally proposed as a direct result of −omics investigations. For their 
subsequent validation, it is essential to possess over highly specific probes that can detect those 
potential candidates. Antibodies are the natural molecules that fulfill the role of specific reporter 
molecules in vertebrates. In the post-genomic era and with high-throughput techniques available, the 
goal is to discriminate between all individual proteins from the proteome including their splice variants 
and post-translationally modified derivatives. Aided by advances in generation, selection and 
engineering of antibody-based recognition units, biosensors provide tools for improved diagnostics and 
biomarker discovery through detection of high- as well as low-abundant analytes even in complex, 
non-fractionated proteomes in conjunction with usage of small amounts of samples and reagents. 
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